COG Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox IND# 103, 331) during Consolidation: A Phase III Study Limited to COG institutions in the United States & Canada Pediatric CIRB Closed to Accrual. Pts Have Completed Intervention Completed